Synthetic compound reverses mutant p53 aggregate accumulation, study shows
Cancer is a multidisciplinary disease, with different mutations leading to different prognoses and treatment necessities. Among the most important mutation targets in cancers, affecting more than 50% of all cancer cases, is TP53.